PortalPublikationenEvaluation of lymphovascular invasion as a prognostic predic...

Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy

Standard

Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. / Rakic, Nikola; Jamil, Marcus; Keeley, Jacob; Sood, Akshay; Vetterlein, Malte; Dalela, Deepansh; Arora, Sohrab; Modonutti, Daniele; Bronkema, Chandler; Novara, Giacomo; Peabody, James; Rogers, Craig; Menon, Mani; Abdollah, Firas.

in: UROL ONCOL-SEMIN ORI, Jahrgang 39, Nr. 8, 08.2021, S. 495.e1-495.e6.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rakic, N, Jamil, M, Keeley, J, Sood, A, Vetterlein, M, Dalela, D, Arora, S, Modonutti, D, Bronkema, C, Novara, G, Peabody, J, Rogers, C, Menon, M & Abdollah, F 2021, 'Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy', UROL ONCOL-SEMIN ORI, Jg. 39, Nr. 8, S. 495.e1-495.e6. https://doi.org/10.1016/j.urolonc.2021.01.007

APA

Rakic, N., Jamil, M., Keeley, J., Sood, A., Vetterlein, M., Dalela, D., Arora, S., Modonutti, D., Bronkema, C., Novara, G., Peabody, J., Rogers, C., Menon, M., & Abdollah, F. (2021). Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. UROL ONCOL-SEMIN ORI, 39(8), 495.e1-495.e6. https://doi.org/10.1016/j.urolonc.2021.01.007

Vancouver

Rakic N, Jamil M, Keeley J, Sood A, Vetterlein M, Dalela D et al. Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. UROL ONCOL-SEMIN ORI. 2021 Aug;39(8):495.e1-495.e6. https://doi.org/10.1016/j.urolonc.2021.01.007

Bibtex

@article{28ee97c97b4541539cb38dcef0d50f08,
title = "Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy",
abstract = "OBJECTIVE: To assess the prognostic ability of lymphovascular invasion (LVI) as a predictor of overall survival (OS).MATERIALS AND METHODS: We included 126,682 prostate cancer (CaP) cM0 patients who underwent radical prostatectomy with lymph node dissection between 2010 and 2015, within the National Cancer Database. Patients who received androgen deprivation therapy were included. Patients were divided into four sub-cohorts based on LVI and lymph node invasion (LNI) status: pL0N0, pL1N0, pL0N1, and pL1N1. Kaplan-Meier curves estimated OS and Cox-regression analysis tested the relationship between LVI and OS.RESULTS: Median (IQR) age and PSA at diagnosis were 62 (57-66) years and 5.7 (4.5-8.9) ng/ml, respectively. Most patients had pT2 stage (68.5%), and pathological Gleason 3+4 (46.7%). 10.0% and 4.0% patients had LVI and LNI, respectively. Median follow-up was 42 months (27-58). At 5-years, OS was 96.5% in pL0N0 patients vs 93.1% pL1N0 patients vs 93.3% in pL0N1 patients vs 86.6% pL1N1 patients. LVI was an independent predictor of OS (hazard ratio [HR]:1.28). LVI showed interaction with LNI, as LVI was associated with a higher overall-mortality in patients with LNI (HR:1.66), than in patients without LNI (HR:1.22). (all P<0.0001) CONCLUSIONS: Our report highlights the detrimental impact of LVI on OS. Patients with LVI alone fared similarly to patients with LNI alone. Patients with both LVI and LNI had worse OS than those with only LVI or LNI, implying a synergetic detrimental interaction. Our findings demonstrate an important utility that LVI can provide in deciding patients' prognoses.",
author = "Nikola Rakic and Marcus Jamil and Jacob Keeley and Akshay Sood and Malte Vetterlein and Deepansh Dalela and Sohrab Arora and Daniele Modonutti and Chandler Bronkema and Giacomo Novara and James Peabody and Craig Rogers and Mani Menon and Firas Abdollah",
note = "Copyright {\textcopyright} 2021. Published by Elsevier Inc.",
year = "2021",
month = aug,
doi = "10.1016/j.urolonc.2021.01.007",
language = "English",
volume = "39",
pages = "495.e1--495.e6",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy

AU - Rakic, Nikola

AU - Jamil, Marcus

AU - Keeley, Jacob

AU - Sood, Akshay

AU - Vetterlein, Malte

AU - Dalela, Deepansh

AU - Arora, Sohrab

AU - Modonutti, Daniele

AU - Bronkema, Chandler

AU - Novara, Giacomo

AU - Peabody, James

AU - Rogers, Craig

AU - Menon, Mani

AU - Abdollah, Firas

N1 - Copyright © 2021. Published by Elsevier Inc.

PY - 2021/8

Y1 - 2021/8

N2 - OBJECTIVE: To assess the prognostic ability of lymphovascular invasion (LVI) as a predictor of overall survival (OS).MATERIALS AND METHODS: We included 126,682 prostate cancer (CaP) cM0 patients who underwent radical prostatectomy with lymph node dissection between 2010 and 2015, within the National Cancer Database. Patients who received androgen deprivation therapy were included. Patients were divided into four sub-cohorts based on LVI and lymph node invasion (LNI) status: pL0N0, pL1N0, pL0N1, and pL1N1. Kaplan-Meier curves estimated OS and Cox-regression analysis tested the relationship between LVI and OS.RESULTS: Median (IQR) age and PSA at diagnosis were 62 (57-66) years and 5.7 (4.5-8.9) ng/ml, respectively. Most patients had pT2 stage (68.5%), and pathological Gleason 3+4 (46.7%). 10.0% and 4.0% patients had LVI and LNI, respectively. Median follow-up was 42 months (27-58). At 5-years, OS was 96.5% in pL0N0 patients vs 93.1% pL1N0 patients vs 93.3% in pL0N1 patients vs 86.6% pL1N1 patients. LVI was an independent predictor of OS (hazard ratio [HR]:1.28). LVI showed interaction with LNI, as LVI was associated with a higher overall-mortality in patients with LNI (HR:1.66), than in patients without LNI (HR:1.22). (all P<0.0001) CONCLUSIONS: Our report highlights the detrimental impact of LVI on OS. Patients with LVI alone fared similarly to patients with LNI alone. Patients with both LVI and LNI had worse OS than those with only LVI or LNI, implying a synergetic detrimental interaction. Our findings demonstrate an important utility that LVI can provide in deciding patients' prognoses.

AB - OBJECTIVE: To assess the prognostic ability of lymphovascular invasion (LVI) as a predictor of overall survival (OS).MATERIALS AND METHODS: We included 126,682 prostate cancer (CaP) cM0 patients who underwent radical prostatectomy with lymph node dissection between 2010 and 2015, within the National Cancer Database. Patients who received androgen deprivation therapy were included. Patients were divided into four sub-cohorts based on LVI and lymph node invasion (LNI) status: pL0N0, pL1N0, pL0N1, and pL1N1. Kaplan-Meier curves estimated OS and Cox-regression analysis tested the relationship between LVI and OS.RESULTS: Median (IQR) age and PSA at diagnosis were 62 (57-66) years and 5.7 (4.5-8.9) ng/ml, respectively. Most patients had pT2 stage (68.5%), and pathological Gleason 3+4 (46.7%). 10.0% and 4.0% patients had LVI and LNI, respectively. Median follow-up was 42 months (27-58). At 5-years, OS was 96.5% in pL0N0 patients vs 93.1% pL1N0 patients vs 93.3% in pL0N1 patients vs 86.6% pL1N1 patients. LVI was an independent predictor of OS (hazard ratio [HR]:1.28). LVI showed interaction with LNI, as LVI was associated with a higher overall-mortality in patients with LNI (HR:1.66), than in patients without LNI (HR:1.22). (all P<0.0001) CONCLUSIONS: Our report highlights the detrimental impact of LVI on OS. Patients with LVI alone fared similarly to patients with LNI alone. Patients with both LVI and LNI had worse OS than those with only LVI or LNI, implying a synergetic detrimental interaction. Our findings demonstrate an important utility that LVI can provide in deciding patients' prognoses.

U2 - 10.1016/j.urolonc.2021.01.007

DO - 10.1016/j.urolonc.2021.01.007

M3 - SCORING: Journal article

C2 - 33602620

VL - 39

SP - 495.e1-495.e6

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 8

ER -